Please save/export the filled in form as PDF before submitting it to Ugeskrift for Læger or Danish Medical Journal.

Date: 19. januar 2023			
Your name: Martin Lund Kårhus			
Manuscript title: Galdesyrediarré – en skjult folkesygdom			
Manuscript number (if known): UFL-09-22-0528			

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

Tim	e frame: Since the initial plar	Name all entities with whom you have this relationship or indicate none (add rows as needed) nning of the work	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	None	
	No time limit for this item.		

Click TAB in last row to add extra rows

2	Grants or contracts from	⊠ None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	⊠ None	

4	Consulting fees	⊠ None
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None
6	Payment for expert testimony	⊠ None
7	Support for attending meetings and/or travel	⊠ None
8	Patents planned, issued or pending	⊠ None
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	⊠ None
11	Stock or stock options	⊠ None
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	☑ None    Image: Second
13	Other financial or non- financial interests	⊠ None

 $\boxtimes$  I certify that I have answered every question and have not altered the wording of any of the questions on this form.

### IMPORTANT for Ugeskrift for Læger & Danish Medical Journal

Please save/export the filled in form as PDF before submitting it to Ugeskrift for Læger or Danish Medical Journal.

Date: 20. januar 2023			
Your name: Anne-Marie Ellegaard			
Manuscript title: Galdesyrediarré – en skjult folkesygdom			
Manuscript number (if known): UFL-09-22-0528			

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

Time frame: Since the initial plan	Name all entities with whom you have this relationship or indicate none (add rows as needed) ning of the work	Specifications/Comments (e.g., if payments were made to you or to your institution)
1 All support for the present	⊠ None	
manuscript (e.g., funding,		
provision of study		
materials, medical writing,		
article processing charges, etc.)		
No time limit for this		
item.		

Click TAB in last row to add extra rows

2	Grants or contracts from	⊠ None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	⊠ None	

4	Consulting fees	⊠ None
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None
6	Payment for expert testimony	⊠ None
7	Support for attending meetings and/or travel	⊠ None
8	Patents planned, issued or pending	⊠ None
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	⊠ None
11	Stock or stock options	⊠ None
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	☑ None    Image: Second
13	Other financial or non- financial interests	⊠ None

 $\boxtimes$  I certify that I have answered every question and have not altered the wording of any of the questions on this form.

### IMPORTANT for Ugeskrift for Læger & Danish Medical Journal

Please save/export the filled in form as PDF before submitting it to Ugeskrift for Læger or Danish Medical Journal.

Date: 19. januar 2023			
Your name: Iben Rix Petersen			
Manuscript title: Galdesyrediarré – en skjult folkesygdom			
Manuscript number (if known): UFL-09-22-0528			

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

Time frame: Since the initial plan	Name all entities with whom you have this relationship or indicate none (add rows as needed) ning of the work	Specifications/Comments (e.g., if payments were made to you or to your institution)
1 All support for the present	⊠ None	
manuscript (e.g., funding,		
provision of study		
materials, medical writing,		
article processing charges, etc.)		
No time limit for this		
item.		

Click TAB in last row to add extra rows

2	Grants or contracts from	⊠ None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	⊠ None	

4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations,	⊠ None	1
	speakers bureaus,		
	manuscript writing or educational events		
	educational events		
6	Payment for expert	🖾 None	
	testimony		
7	Support for attending	⊠ None	
	meetings and/or travel		
8	Patents planned, issued or pending	⊠ None	1
	pending		
9	Participation on a Data	None	•
,	Safety Monitoring Board		
	or Advisory Board		
10	Leadership or fiduciary	⊠ None	
	role in other board,		
	society, committee or advocacy group, paid or		
	unpaid		
11	Stock or stock options		1
	Stock of Stock options	⊠ None	
12	Receipt of equipment,	⊠ None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-		
	financial interests	2018-2021	Industrial PhD-student employed by Zealand Pharma A/S

I certify that I have answered every question and have not altered the wording of any of the questions on this form.

### IMPORTANT for Ugeskrift for Læger & Danish Medical Journal

Please save/export the filled in form as PDF before submitting it to Ugeskrift for Læger or Danish Medical Journal.

Date: 20. januar 2023		
Your name: Filip Krag Knop		
Manuscript title: Galdesyrediarré – en skjult folkesygdom		
Manuscript number (if known): UFL-09-22-0528		

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

Tim	e frame: Since the initial plar	Name all entities with whom you have this relationship or indicate none (add rows as needed) nning of the work	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	None	
	No time limit for this item.		

Click TAB in last row to add extra rows

2	Grants or contracts from		
	any entity (if not indicated	AstraZeneca	Investigatior-initiated studies
	in item #1 above).	Gubra	Investigator-initiated studies
		Novo Nordisk	Investigator-initiated studies
		Sanofi	Investigator-initiated studies
		Zealand Pharma	Investigator-initiated studies
	•	-	
3	Royalties or licenses	⊠ None	

<u> </u>			
4	Consulting fees	□ None	
		Carmot Therapeutics	Scientific advise
		Eli Lilly	Consulting
		Novo Nordisk	Consulting
		Sanofi	Consulting
		Zealand Pharma	Consulting
5	Payment or honoraria for	□ None	
	lectures, presentations, speakers bureaus, manuscript writing or educational events	AstraZeneca	Educational activities (lecturing, teaching)
		Boehringer Ingelheim	Educational activities (lecturing, teaching)
		Eli Lilly	Educational activities (lecturing, teaching)
		MedImmune	Educational activities (lecturing, teaching)
		MSD/Merck	Educational activities (lecturing, teaching)
		Norgine	Educational activities (lecturing, teaching)
		Novo Nordisk	Educational activities (lecturing, teaching)
		Sanofi	Educational activities (lecturing, teaching)
		Zealand Pharma	Educational activities (lecturing, teaching)
		Bayer	Lecturing
6	Payment for expert	⊠ None	
	testimony		
	5		
7	Support for attending	□ None	
	meetings and/or travel	Bayer	Travelling to scientific meetings
		Novo Nordisk	Travelling to scientific meetings
		MSD/Merck	Travelling to scientific meetings
		Eli Lilly	Travelling to scientific meetings
8	Patents planned, issued or	⊠ None	
	pending		
		·	
9	Participation on a Data	□ None	
	Safety Monitoring Board	AstraZeneca	Advisory board
	or Advisory Board	Boehringer Ingelheim	Advisory board
		Eli Lilly	Advisory board
		MedImmune	Advisory board
		MSD/Merck	Advisory board
		Novo Nordisk	Advisory board
		Sanofi	Advisory board
		Zealand Pharma	Advisory board
		ShouTi	Advisory board
		Zucara	Advisory board
10	Leadership or fiduciary	🖾 None	
	role in other board,		
	society, committee or		
	advocacy group, paid or		
	unpaid		
11	Stock or stock ontions		
11	Stock or stock options	⊠ None	

12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	⊠ None
13	Other financial or non- financial interests	⊠ None

 $\boxtimes$  I certify that I have answered every question and have not altered the wording of any of the questions on this form.

### IMPORTANT for Ugeskrift for Læger & Danish Medical Journal